European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Dateline City:

PRINCETON, N.J.

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers
Squibb Company (NYSE: BMY) today announced that the European
Commission (EC) has approved Sprycel (dasatinib) in combination
with chemotherapy for the treatment of pediatric patients with newly
diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic
leukemia (ALL). This is the second pediatric leukemia indication for Sprycel
in Europe.
Language:

English

Contact:

Media: Kirby Hosea, 609-302-4399 [email protected] Investor: Bill Szablewski, 609-252-5894 [email protected] Tim Power, 609-252-7509 [email protected]

Ticker Slug:

Ticker: BMY Exchange: NYSE

$BMY receives approval from European Commission to expand indication for therapy to include certain pediatric patients with acute lymphoblastic #leukemia:

read more

Original Source